AMNEAL PHARMACEUTICALS, INC. Business Acquisition, Pro Forma Net Income (Loss)
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Business Acquisition, Pro Forma Net Income (Loss) of $22.52 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2023-03-03
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2021-12-31 was -$20.33M.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2021-09-30 was -$5.96M.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2020-12-31 was -$6.84M.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2020-09-30 was -$24.74M.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for fiscal 2021 was $22.52M, a 58.35% decline from fiscal 2020.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for fiscal 2020 was $54.08M.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for fiscal 2019 was -$594.04M.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for fiscal 2018 was -$163.91M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | -$20.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$26.29M derived: sum of 2 quarters · filed 2023-03-03 | $22.52M 10-K · filed 2023-03-03 | |||||
| 2021-09-30 | -$5.96M 10-Q · filed 2021-11-08 | $42.85M 10-Q · filed 2021-11-08 | ||||||
| 2020-12-31 | -$6.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$31.58M derived: sum of 2 quarters · filed 2023-03-03 | $2.60M derived: sum of 3 quarters · filed 2023-03-03 | $54.08M 10-K · filed 2023-03-03 | $68.59M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$24.74M 10-Q · filed 2021-11-08 | -$22.03M 10-Q · filed 2020-11-06 | $9.44M derived: sum of 2 quarters · filed 2021-11-08 | $60.92M 10-Q · filed 2021-11-08 | $75.55M 10-Q · filed 2020-11-06 | $73.89M derived: sum of 4 quarters · filed 2021-11-08 | ||
| 2020-06-30 | $34.17M 10-Q · filed 2021-08-09 | -$23.94M 10-Q · filed 2020-08-06 | $49.20M 10-Q · filed 2021-08-09 | $92.47M 10-Q · filed 2020-08-06 | $98.63M derived: sum of 3 quarters · filed 2021-08-09 | -$259.34M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | $122.52M 10-Q · filed 2021-05-07 | $64.46M derived: sum of 2 quarters · filed 2021-05-07 | -$293.51M derived: sum of 3 quarters · filed 2021-05-07 | -$319.74M derived: sum of 4 quarters · filed 2021-08-09 | ||||
| 2019-12-31 | -$58.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$416.03M derived: sum of 2 quarters · filed 2021-03-01 | -$442.26M derived: sum of 3 quarters · filed 2021-08-09 | -$594.04M 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | -$357.97M 10-Q · filed 2020-11-06 | -$384.20M derived: sum of 2 quarters · filed 2021-08-09 | -$535.98M 10-Q · filed 2020-11-06 | -$537.94M derived: sum of 4 quarters · filed 2021-08-09 | ||||
| 2019-06-30 | -$26.23M 10-Q · filed 2021-08-09 | -$45.62M 10-Q · filed 2020-08-06 | $85.94M 10-Q · filed 2021-08-09 | -$178.01M 10-Q · filed 2020-08-06 | -$179.97M derived: sum of 3 quarters · filed 2021-08-09 | -$162.50M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2019-03-31 | -$133.41M 10-Q · filed 2020-05-11 | -$153.74M derived: sum of 2 quarters · filed 2020-05-11 | -$136.28M derived: sum of 3 quarters · filed 2020-05-11 | -$222.90M derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | -$20.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$2.87M derived: sum of 2 quarters · filed 2020-03-02 | -$89.49M derived: sum of 3 quarters · filed 2020-03-02 | -$163.91M 10-K · filed 2020-03-02 | ||||
| 2018-09-30 | $17.46M 10-Q · filed 2018-11-07 | -$69.16M derived: sum of 2 quarters · filed 2019-08-05 | -$143.59M 10-Q · filed 2019-11-07 | -$113.17M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | -$86.62M 10-Q · filed 2019-08-05 | -$161.05M 10-Q · filed 2019-08-05 | -$130.63M derived: sum of 3 quarters · filed 2020-03-02 | -$160.61M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | -$74.08M 10-Q · filed 2019-05-09 | -$44.01M derived: sum of 2 quarters · filed 2020-03-02 | -$73.99M derived: sum of 3 quarters · filed 2020-03-02 | -$78.19M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $30.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $88.00K derived: sum of 2 quarters · filed 2020-03-02 | -$4.11M derived: sum of 3 quarters · filed 2020-03-02 | -$340.22M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | -$29.98M 10-Q · filed 2018-11-07 | -$34.17M derived: sum of 2 quarters · filed 2018-11-07 | -$370.29M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | -$4.20M 10-Q · filed 2018-08-09 | -$340.31M 10-Q · filed 2018-08-09 | ||||||
| 2016-12-31 | -$535.09M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |